1268474-32-3

Upstream product

• 256446-67-0 4-((benzyloxy)carbonyl)morpholine-3-carboxylic acid 
• 1268475-07-5 2-chloro-5-(2,2-difluoropropyl)-6a,7,9,10-tetrahydro[1,4]oxazino[3,4-h]pteridin -6(5H)-one 
• 1268475-19-9 2-chloro-5-(2-oxopropyl)-6a,7,9,10-tetrahydro[1,4]oxazino[3,4-h]pteridin-6(5H)-one 
• 1268474-29-8 1-cyclopropyl-3-(4-(5-(2,2-difluoropropyl)-6a-methyl-6-oxo-5,6,6a,7,9,10-hexahydro[1,4]oxazino[3,4-h]pteridin-2-yl)phenyl)urea 
• 1268474-50-5 2-chloro-6a,7,9,10-tetrahydro[1,4]oxazino[3,4-h]pteridin -6(5H)-one 
• 874297-79-7 1-cyclopropyl-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)urea 
• 1268475-08-6 2-chloro-5-(2,2-difluoropropyl)-6a-methyl-6a,7,9,10-tetrahydro[1,4]oxazino[3,4-h]pteridin-6(5H)-one 
• 77873-76-8 morpholine-3-carboxylic acid 

Relevant academic research and scientific papers

Rational discovery of a highly novel and selective mTOR inhibitor

Aided by Structure Based Drug Discovery (SBDD), we rapidly designed a highly novel and selective series of mTOR inhibitors. This chemotype conveys exquisite kinase selectivity, excellent in vitro and in vivo potencies and ADME safety profiles. These compo

HEXAHYDROOXAZINOPTERINE COMPOUNDS

The present invention provides mTOR inhibitors of the formula wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods of making the compounds and intermediates thereof; and methods of using the compounds.